Cargando…

Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myeloma

Multiple Myeloma is an incurable plasma cell malignancy with a poor survival rate that is usually treated with immunomodulatory drugs (iMiDs) and proteosome inhibitors (PIs). The malignant plasma cells quickly become resistant to these agents causing relapse and uncontrolled growth of resistant clon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Travis S., Sudha, Parvathi, Liu, Enze, Blaney, Patrick, Morgan, Gareth, Chopra, Vivek S., Santos, Cedric Dos, Nixon, Michael, Huang, Kun, Suvannasankha, Attaya, Zaid, Mohammad Abu, Abonour, Rafat, Walker, Brian A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462227/ https://www.ncbi.nlm.nih.gov/pubmed/37645789 http://dx.doi.org/10.21203/rs.3.rs-3221549/v1

Ejemplares similares

Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma
por: Liu, Enze, et al.
Publicado: (2023)

DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
por: Prawitz, Thibaud, et al.
Publicado: (2021)

Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer
por: Ghamlouch, Hussein, et al.
Publicado: (2021)

S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lee, Hans C., et al.
Publicado: (2023)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009)

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
por: Sudha, Parvathi, et al.
Publicado: (2022)

Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis
por: Dejhansathit, Siroj, et al.
Publicado: (2019)

Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway
por: Liu, Enze, et al.
Publicado: (2023)

Role of bone-anabolic agents in the treatment of breast cancer bone metastases
por: Suvannasankha, Attaya, et al.
Publicado: (2014)

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
por: Lonial, Sagar, et al.
Publicado: (2021)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
por: Davies, Faith, et al.
Publicado: (2021)

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
por: Bhatt, Parva, et al.
Publicado: (2023)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
por: Yang, Wen-Chi, et al.
Publicado: (2015)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

How I treat relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2020)

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
por: Podar, Klaus, et al.
Publicado: (2021)

Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
por: Ehsan, Hamid, et al.
Publicado: (2021)

Optimal sequencing in the management of relapsed/refractory myeloma patients
por: Moreau, Philippe
Publicado: (2018)

Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma
por: Rodriguez, Cesar, et al.
Publicado: (2023)

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL
por: Nooka, A., et al.
Publicado: (2023)

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
por: Rasche, Leo, et al.
Publicado: (2022)

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY
por: Suvannasankha, A., et al.
Publicado: (2022)

Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease
por: Mason, Mike J., et al.
Publicado: (2020)

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
por: Fostier, Karel, et al.
Publicado: (2012)

The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
por: Becnel, Melody R., et al.
Publicado: (2020)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
por: Su, Christopher T., et al.
Publicado: (2021)

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
por: Young, Mary H., et al.
Publicado: (2021)

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
por: Matsue, Kosei, et al.
Publicado: (2015)

GFI1-Dependent Repression of SGPP1 Increases Multiple Myeloma Cell Survival
por: Petrusca, Daniela N., et al.
Publicado: (2022)

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
por: Richardson, Paul G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1pl8aa5mtm39u7qd7lprsm44ue